For the Inventor, By the Inventor

Enter assignee name

Biocytogen Pharmaceuticals (beijing) Co., Ltd.

USPTO Granted Patents = 33

Trademarks = 8

Forward Citations = 8

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Yuelei Shen (33 out of 45 patents)

Yang Bai (27 out of 66 patents)

Yanan Guo (27 out of 40 patents)

4. Rui Huang (25 out of 167 patents)

5. Jiawei Yao (20 out of 21 patents)

6. Meiling Zhang (17 out of 18 patents)

7. Xiaofei Zhou (13 out of 15 patents)

8. Chaoshe Guo (13 out of 13 patents)

9. Lei Zhao (8 out of 48 patents)

10. Chengzhang Shang (7 out of 8 patents)

11. Jian Ni (4 out of 14 patents)

12. Chen Wang (4 out of 65 patents)

13. Yabo Zhang (3 out of 6 patents)

14. Hui Lu (3 out of 16 patents)

15. Huizhen Zhao (3 out of 3 patents)

33 patents: Sort by Forward Citations

1. 12342800 - Immunodeficient non-human animal (2025-07-01),

2. 12180281 - Anti-PD-1 antibodies and methods of treating cancer (2024-12-31),

3. 12016315 - Genetically modified non-human animal with human or chimeric CD3e (2024-06-25),

4. 12004495 - Genetically modified non-human animals with humanized immunoglobulin locus (2024-06-11),

5. 11997994 - Genetically modified non-human animals with common light chain immunoglobulin locus (2024-06-04),

6. 11987615 - Modified immunoglobulins (2024-05-21),

7. 11730151 - Genetically modified non-human animals with humanized immunoglobulin locus (2023-08-22),

8. 11723348 - Genetically modified mice expressing humanized CD47 (2023-08-15),

9. 11564381 - Genetically modified non-human animal with human or chimeric LAG3 (2023-01-31),

10. 11534502 - Genetically modified non-human animal with human or chimeric TIGIT (2022-12-27),

11. 11505806 - Genetically modified non-human animal with human or chimeric OX40 (2022-11-22),

12. 11497198 - Genetically modified mice expressing humanized CD40 (2022-11-15),

13. 11464876 - Genetically modified mouse comprising a chimeric TIGIT (2022-10-11),

14. 11439132 - Humanized transgenic animal (2022-09-13),

15. 11352429 - Anti-PD-1 antibodies and uses thereof (2022-06-07),

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a leading biotechnology company specializing in innovative antibody discovery and development, preclinical/clinical drug development, and precision medicine solutions. With expertise in antibody engineering, animal model creation, and CRISPR/Cas9 gene editing technology, Biocytogen is dedicated to advancing biomedical research and revolutionizing drug discovery. Visit our website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

33 Patents

#113 in Beijing

#852 in China

#19,543 in the World

Biocytogen Pharmaceuticals (beijing) Co., Ltd.

Forward Citations = 8

26 inventors:

Yuelei Shen (33 out of 45 patents)

Yang Bai (27 out of 66 patents)

Yanan Guo (27 out of 40 patents)

4. Rui Huang (25 out of 167 patents)

5. Jiawei Yao (20 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…